Anixa Biosciences Inc. (NASDAQ:ANIX) shares fell to a low of $2.85 before closing at $3.14. Intraday shares traded counted 16.86 million, which was -8749.37% lower than its 30-day average trading volume of 190.50K. ANIX’s previous close was $2.89 while the outstanding shares total 23.17M. The firm has a beta of 1.58. The stock’s Relative Strength Index (RSI) is 67.12, with weekly volatility at 24.77% and ATR at 0.38. The ANIX stock’s 52-week price range has touched low of $1.33 and a $4.13 high. The stock traded higher over the last trading session, gaining 8.65% on 12/10/20.
Investors have identified the Diagnostics & Research company Anixa Biosciences Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $72.57 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Anixa Biosciences Inc. (ANIX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 9.26 million total, with 1.21 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.51 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ANIX sounds very interesting.
Is the stock of ANIX attractive?
In related news, Chief Executive Officer, KUMAR AMIT bought 28,000 shares of the company’s stock in a transaction that recorded on Sep 11. The purchase was performed at an average price of 2.11, for a total value of 59,080. As the purchase deal closes, the Director, Titterton Lewis H jr now bought 40,000 shares of the company’s stock, valued at 83,200. Also, Director, Titterton Lewis H jr bought 24,500 shares of the company’s stock in a deal that was recorded on Jun 16. The shares were cost at an average price of 2.27 per share, with a total market value of 55,615. Following this completion of disposal, the Director, Titterton Lewis H jr now holds 31,083 shares of the company’s stock, valued at 70,558. In the last 6 months, insiders have changed their ownership in shares of company stock by 5.40%.